Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?
Osteoporosis International · 2026
DOI: 10.1007/s00198-025-07798-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Osteoporosis International, 2026. Verfasst von G Marcucci und 14 weiteren Autor:innen. Beteiligte Einrichtung: Bone Metabolic Diseases Unit, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Denosumab, Breast Neoplasms, Aromatase Inhibitors, Bone Density Conservation Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 126 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Aromatase inhibitors (AIs) are one of the adjuvant endocrine therapies of choice, for estrogen receptor-positive breast cancer in postmenopausal women and premenopausal women with ovarian suppression. However, treatment with AIs leads to accelerated bone loss, and an increased fracture risk. Denosumab or bisphosphonates are recommended to prevent bone loss and reduce fracture risk during AIs treatment. However, specific attention must be paid to the "rebound phenomenon" after denosumab discontinuation. This review focuses on the therapeutic benefits of denosumab for its antiresorptive and antifracture effect in women with early breast cancer treated with AIs, risks related to denosumab discontinuation after treatment with AIs, prevention, and potential interventions for its associated fracture risk. A narrative review of available literature was carried out by International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease. Papers were retrieved by means of a PubMed enquiry (from 2006 to August 2025). A total of 126 papers closely related to our topic were included. After denosumab withdrawal in women with breast cancer treated with AIs, bone turnover increases, and there is a risk of spontaneous rebound-associated vertebral fractures, even in the absence of other risk factors for bone fragility. Therefore, expert consensus suggests initiating bisphosphonate treatment after denosumab discontinuation, even though there is no an optimal bisphosphonate regimen. There are numerous open research questions which future prospective studies will have to answer in order to personalize the most appropriate antiresorptive therapy for each patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Metabolic Diseases Unit, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, Italy.
- Division of Bone Diseases, Department of Medicine, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland.
- Department of Medicine, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.
- Department of Medicine, Clinica Universidad de los Andes y Universidad de los Andes, Santiagode , Chile.
- Bone and Mineral Research Unit, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias, Universidad de Oviedo, Retic REDinREN-ISCIII, Avda. Roma, Sn., , 33011,…
- Department of Rheumatology South, UMR1033 LYOS-Bone Metastasis Expert Center (CEMOS), Cancer Institute of Hospices Civils de Lyon, Université Claude Bernard Lyon, 1-INSERM, Lyon, France.
Zitieren
APA
Marcucci, G., Biver, E., Body, J. J., Campusano, C., Cannata-Andía, J., Confavreux, C., de Villiers, T. J., Ebeling, P. R., Hadji, P., Kendler, D., El Maghraoui, A., Napoli, N., Veronesi, P., Rizzoli, R., & Brandi, M. L. (2026). Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?. Osteoporosis International. https://doi.org/10.1007/s00198-025-07798-2
Vancouver
Marcucci G, Biver E, Body JJ, Campusano C, Cannata-Andía J, Confavreux C, et al. Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?. Osteoporosis International. 2026. doi:10.1007/s00198-025-07798-2
BibTeX
@article{Marcucci2026,
author = {Marcucci, G and Biver, E and Body, J J and Campusano, C and Cannata-Andía, J and Confavreux, C and de Villiers, T J and Ebeling, P R and Hadji, P and Kendler, D and El Maghraoui, A and Napoli, N and Veronesi, P and Rizzoli, R and Brandi, M L},
title = {Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?},
journal = {Osteoporosis International},
year = {2026},
doi = {10.1007/s00198-025-07798-2}
}
EUVIMED